Expression of microRNAs 16, 20a, 150 and 155 in anal squamous intraepithelial lesions from high-risk groups.
Adult
Anus Neoplasms
/ genetics
Biomarkers, Tumor
/ genetics
Carcinoma in Situ
/ genetics
Case-Control Studies
Female
Humans
Male
MicroRNAs
/ genetics
Papillomaviridae
/ isolation & purification
Papillomavirus Infections
/ complications
Precancerous Conditions
/ genetics
Prognosis
Risk Factors
Squamous Intraepithelial Lesions
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 02 2019
06 02 2019
Historique:
received:
22
08
2018
accepted:
27
12
2018
entrez:
8
2
2019
pubmed:
8
2
2019
medline:
1
9
2020
Statut:
epublish
Résumé
Anal squamous intraepithelial lesions (ASIL) or anal intraepithelial neoplasia (AIN) are precancerous lesions. microRNAs (miRNAs) have been implicated in cervical carcinogenesis, but have never been assessed in anal precancerous lesions. Our aim was to evaluate the expression of miR-16, miR-20a, miR-150 and miR-155 in several grades of ASIL obtained from high-risk patients, submitted to anal cancer screening from July 2016 to January 2017. Lesions were classified according to the Lower Anogenital Squamous Terminology (LAST) in low-grade (LSIL) and high-grade squamous intraepithelial lesions (HSIL), and the AIN classification in AIN1, AIN2 and AIN3. A hundred and five biopsies were obtained from 60 patients. Ten samples were negative (9.5%), 63 were LSIL (60%) and 32 were HSIL (30.5%) according to the LAST. Twenty seven (26%) were negative for dysplasia, 46 were classified as AIN1 (44%), 14 as AIN2 (13%) and 18 as AIN3 (17%) according to the AIN classification. There was no statistically significant difference in the fold expression of miR-16, miR-20a, miR-150 and miR-155, according to either classification. Although non- significant, there was an increasing trend in the miR-155 fold expression from negative samples to HSIL, with the highest fold expression increase in both LSIL and HSIL compared to the other miRNAs.
Identifiants
pubmed: 30728437
doi: 10.1038/s41598-018-38378-6
pii: 10.1038/s41598-018-38378-6
pmc: PMC6365520
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN150 microRNA, human
0
MIRN155 microRNA, human
0
MIRN16 microRNA, human
0
MIRN20a microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1523Références
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Lancet. 1992 Nov 21;340(8830):1271-3
pubmed: 1359331
Br J Cancer. 2003 Oct 6;89(7):1221-7
pubmed: 14520450
Lancet. 1991 Sep 14;338(8768):657-9
pubmed: 1679474
Nat Med. 2007 Oct;13(10):1241-7
pubmed: 17906637
PLoS One. 2008 Jul 02;3(7):e2557
pubmed: 18596939
Nat Genet. 2009 Feb;41(2):221-7
pubmed: 19151717
Gynecol Oncol. 2009 Sep;114(3):395-8
pubmed: 19501390
J Low Genit Tract Dis. 2009 Jul;13(3):145-53
pubmed: 19550211
Cancer. 2010 Sep 15;116(18):4275-82
pubmed: 20549820
J Pathol. 2011 Jan;223(2):102-15
pubmed: 21125669
Med Oncol. 2012 Jun;29(2):1242-8
pubmed: 21264530
J Pathol. 2011 Aug;224(4):484-95
pubmed: 21503900
Am J Obstet Gynecol. 2011 Aug;205(2):115.e1-5
pubmed: 21684518
Clin Med Pathol. 2008;1:7-13
pubmed: 21876646
Retrovirology. 2012 Jan 12;9:5
pubmed: 22240256
Oncogene. 2013 Jan 3;32(1):106-16
pubmed: 22330141
Lancet Oncol. 2012 May;13(5):487-500
pubmed: 22445259
FEBS Lett. 2012 Mar 23;586(6):897-904
pubmed: 22449978
Br J Cancer. 2012 Apr 24;106(9):1526-34
pubmed: 22472886
Lancet Oncol. 2012 Jun;13(6):e249-58
pubmed: 22652233
J Low Genit Tract Dis. 2012 Jul;16(3):205-42
pubmed: 22820980
BMC Infect Dis. 2013 May 30;13:250
pubmed: 23721325
Asian Pac J Cancer Prev. 2013;14(4):2289-93
pubmed: 23725129
Int J Mol Med. 2013 Sep;32(3):557-67
pubmed: 23799609
Clin Infect Dis. 2014 Jan;58(1):1-10
pubmed: 24343580
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4262-7
pubmed: 24591631
Tumour Biol. 2014 Jul;35(7):7105-13
pubmed: 24760272
PLoS One. 2014 May 14;9(5):e95920
pubmed: 24828336
Tumour Biol. 2014 Dec;35(12):11933-8
pubmed: 25155037
PLoS One. 2015 Mar 24;10(3):e0120905
pubmed: 25803820
PLoS One. 2015 Apr 16;10(4):e0123946
pubmed: 25880806
Int J Cancer. 2016 Mar 15;138(6):1312-27
pubmed: 26032913
Cancer Epidemiol. 2015 Dec;39(6):842-7
pubmed: 26651444
BMC Mol Biol. 2015 Dec 29;16:24
pubmed: 26715362
Br J Cancer. 2016 Oct 25;115(9):1147-1155
pubmed: 27727232
Int J Epidemiol. 2017 Jun 1;46(3):924-938
pubmed: 27789668
Eur Rev Med Pharmacol Sci. 2016 Dec;20(23):4846-4851
pubmed: 27981553
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Papillomavirus Res. 2016 Dec;2:97-105
pubmed: 29074193
Br J Cancer. 2017 Dec 5;117(12):1761-1767
pubmed: 29093575
J Clin Oncol. 2018 Jan 1;36(1):68-75
pubmed: 29140774
Oncotarget. 2017 Oct 11;8(61):103315-103326
pubmed: 29262564
Mod Pathol. 2018 Jul;31(7):1026-1035
pubmed: 29434342
Sci Rep. 2018 May 4;8(1):7070
pubmed: 29728572
Br J Surg. 1994 Mar;81(3):365-7
pubmed: 8173899